Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (1340)	10/28/1998 12:45:00 PM
From: Joe E.	Read Replies (1) \| Respond to of 2135

I couldn't read the article either, but it seems to me that one of the claims in one of the press releases that I did read said that the compound CM101 "protected" nerve cells in culture, whatever that means. Perhaps this makes it unique in some way among the many antiangiogenesis drugs out there. But probably, this morning, some mice are being sacrificed to test Thalidomide and AG3340 and other agents to see what effect they have on spinal cord injuries. A search for CM101 indicates that it is in Phase 1 clinical testing for cancer in humans, and seems safe.

To: tommysdad who wrote (1340)	10/29/1998 7:21:00 AM
From: Cage Rattler	Read Replies (1) \| Respond to of 2135

TD: Very interesting on two counts. 1) How did you slip into that site? Have you tried the link you posted? Were you blocked? 2) Although I have not read the text, the crush-model must involve the Phases II and III of repair following acute injury -- wound cleaning, scar tissue formation, and hypoxia -- recalling that most tissue damage actually occurs as a function of the bodies response to the defining insult. Indeed the concept is viable and very interesting. The CarboMed concept would appear to have numerous traumatology applications. This might be a very profitable venture. Ciao, Ted